AMUNDSEN

objectif

A phase IV, multicentric, randomized, real-world pragmatic study that compares a strategy of early LDL reduction with anti-PCSK9 in patients defined as extreme high risk by 2019 ESC/EAS guidelines vs. Standard of Care as defined by the guidelines but also constrained by current drug availabilities in the different participating countries.